Squarepoint
CTMX icon

Squarepoint’s CytomX Therapeutics CTMX Stock Holding History

Squarepoint’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-109,000
Closed -$129K – 5097
2024
Q3 		$129K Buy
+109,000
New +$138K ﹤0.01% 3817
2024
Q2 		– Sell
-47,000
Closed -$102K – 4156
2024
Q1 		$102K Buy
+47,000
New +$86.7K ﹤0.01% 3793

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's CTMX Position: Q1 2026 in Review

Squarepoint increased its CytomX Therapeutics (CTMX) stake by 383% in Q1 2026, buying an estimated $971K and bringing the position to 241,215 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2667.

Squarepoint first reported a position in CTMX in Q4 2016 and has held it in 33 quarters since. The position peaked at $4.74M in Q2 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Squarepoint held 241,215 shares of CytomX Therapeutics worth $1.13M as of Q1 2026.
  • Squarepoint bought 191,318 CytomX Therapeutics shares in Q1 2026, an estimated $971K.
  • CytomX Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2667 holding.
  • Squarepoint first reported a position in CytomX Therapeutics in Q4 2016 and has held it in 33 quarters since.
  • Squarepoint's CytomX Therapeutics position peaked at $4.74M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.